Critical Survey: SI-BONE (NASDAQ:SIBN) versus QHSLab (OTCMKTS:USAQ)

SI-BONE (NASDAQ:SIBN) and QHSLab (OTCMKTS:USAQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Institutional and Insider Ownership

98.1% of SI-BONE shares are held by institutional investors. 5.4% of SI-BONE shares are held by company insiders. Comparatively, 74.2% of QHSLab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares SI-BONE and QHSLab”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SI-BONE	$138.89 million	4.71	-$43.34 million	($1.09)	-14.40
QHSLab	$1.41 million	0.70	-$470,000.00	N/A	N/A

QHSLab has lower revenue, but higher earnings than SI-BONE.

Risk and Volatility

SI-BONE has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, QHSLab has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500.

Profitability

This table compares SI-BONE and QHSLab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SI-BONE	-27.10%	-24.27%	-17.98%
QHSLab	-11.87%	N/A	-11.18%

Analyst Recommendations

This is a summary of recent ratings for SI-BONE and QHSLab, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SI-BONE	0	0	6	0	3.00
QHSLab	0	0	0	0	N/A

SI-BONE currently has a consensus price target of $23.00, indicating a potential upside of 46.12%. Given SI-BONE’s higher probable upside, equities research analysts plainly believe SI-BONE is more favorable than QHSLab.

Summary

SI-BONE beats QHSLab on 6 of the 11 factors compared between the two stocks.

About SI-BONE

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.